Key Product Specifications Purity: 99% (HPLC verified) with both 1st-party and independent third-party testing Molecular Formula: CHNO Molecular Weight: 4731 g/mol Form: Lyophilized research peptide COA: Full Certificate of Analysis provided for every order Pure Rawz currently offers their Retatrutide at a heavily discounted price of $185.10 (regular $668), making it one of the most cost-effective single-vial options on the market
Because of this, the safety information for Mounjaro has been updated
We convert each of the percentage changes into ratios, divide the treatment ratio by the placebo ratio to get the placebo-corrected ratio, then convert that ratio back to a percentage, in this case -52.1%
The MHRA-approved Summaries of Product Characteristics (SmPCs) for semaglutide, liraglutide and tirzepatide do not list infertility as a recognised adverse effect, though clinical trials were not specifically designed to detect fertility issues

Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)

How this shapes prescriptions and insurance Coverage, prior authorization criteria, and manufacturer savings programs all operate at the product-label level, not the molecule level